Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

Delayed Quote. Delayed  - 09/23 10:00:00 pm
1.25 USD   +12.61%
09/20 CATALYST PHARMA : Announces Publication of CPP-115 Clinical Efficacy..
09/19 Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinica..
09/16 CATALYST PHARMA : Announces Launch of Expanded Access Program Websit..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
1.03(c) 1.06(c) 1.09(c) 1.11(c) 1.25(c) Last
375 978 537 029 806 412 894 335 3 124 517 Volume
+4.04% +2.91% +2.83% +1.83% +12.61% Change
More quotes
Financials ($)
Sales 2016 -
EBIT 2016 -21,8 M
Net income 2016 -21,1 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -26,2 M
Net income 2017 -26,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 104 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
09/20 CATALYST PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Chang..
09/20 CATALYST PHARMACEUTICALS : Announces Publication of CPP-115 Clinical Efficacy Da..
09/19 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
09/19 Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy D..
09/16 CATALYST PHARMACEUTICALS : Announces Launch of Expanded Access Program Website a..
09/14 Catalyst Pharmaceuticals Announces Launch of Expanded Access Program Website ..
09/08 CATALYST PHARMACEUTICALS : to Present at Rodman & Renshaw's 18th Annual Global I..
09/08 Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual G..
09/03 CATALYST PHARMACEUTICALS : Announces FDA Orphan Drug Designation of Firdapse for..
09/02 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/23 Midday Gainers / Losers
09/23 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
08/24 Midday Gainers / Losers
08/24 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 am
08/10 Catalyst Pharmaceutical Partners' (CPRX) CEO Pat McEnany on Q2 2016 Results -..
Advertisement
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Technical analysis trends CATALYST PHARMACE...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 3,63 $
Spread / Average Target 190%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President, CEO & Contact Person
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer
Philip H. Coelho Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICA..-48.98%104
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
CELGENE CORPORATION-8.63%84 821
REGENERON PHARMACEUTIC..-24.40%43 212
VERTEX PHARMACEUTICALS..-27.97%22 456
More Results